TMC310911, Ascletis In-Licenses China Rights to HIV Drug from Janssen

New Drug Approvals

TMC310911, credit pubchem

see structure  http://aac.asm.org/content/55/12/5723/F1.expansion.html

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3232804/  structure available

TMC310911, Ascletis In-Licenses China Rights to HIV Drug from Janssen

Apr 30, 2013

Ascletis, a China-US drug developer, has in-licensed China rights to a next-generation HIV protease inhibitor from Janssen R&D Ireland, a subsidiary of Johnson & Johnson. Janssen believes the drug, known as TMC310911, is likely to prove more effective against drug-resistant strains of HIV than currently available PIs. The molecule is the third drug candidate in-licensed by Ascletis, which is also developing its own siRNA anti-cancer drug candidate.

View original post

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s